Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | IL6 | P05231 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13620040 | 0.87 | DDR1 (0.38) | DDR1USP1TLR7JAK3ADRA2A | |
| SCHEMBL13620361 | 0.84 | DDR1 (0.39) | DDR1USP1JAK3ADRA2AMCHR1 | |
| SCHEMBL13620486 | 0.84 | DDR1 (0.39) | DDR1USP1TLR7JAK3ADRA2A | |
| SCHEMBL13845184 | 0.83 | DDR1 (0.45) | DDR1USP1ADRA2AMCHR1 | |
| SCHEMBL13620384 | 0.83 | DDR1 (0.39) | DDR1USP1TLR7IL6ADRA2A | |
| SCHEMBL13620047 | 0.82 | DDR1 (0.37) | DDR1USP1TLR7ADRA2AMCHR1 | |
| SCHEMBL13620270 | 0.82 | MCHR1 (0.43) | DDR1ADRA2AMCHR1 | |
| SCHEMBL13620495 | 0.81 | DDR1 (0.38) | DDR1USP1JAK3ADRA2AMCHR1 | |
| SCHEMBL13620197 | 0.79 | DDR1 (0.41) | DDR1USP1JAK3ADRA2AMCHR1 | |
| SCHEMBL13620058 | 0.79 | DDR1 (0.39) | DDR1TLR7JAK3ADRA2AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | DDR1 3201/4885USP1 3253/4885OPRM1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.